Displaying 25 - 36 of 114
Immune-Mediated and Cholestatic Diseases
5

Ipsen: Shining a light on unexplained cholestasis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
4

AdvanzPharma: Shifting Paradigms in PBC Management - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
5

Ipsen: Shining a light on unexplained cholestasis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
5

Ipsen: Shining a light on unexplained cholestasis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
5

Ipsen: Shining a light on unexplained cholestasis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
4

AdvanzPharma: Shifting Paradigms in PBC Management - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
4

AdvanzPharma: Shifting Paradigms in PBC Management - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
4

AdvanzPharma: Shifting Paradigms in PBC Management - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
7

GSK: "Practical tips towards providing holistic care to patients with PBC" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Ipsen: "Scratching beyond the surface in PBC: From current unmet medical needs to future prospects" - EASL Congress 2023

View
Displaying 25 - 36 of 114